Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Akeso
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05271292CT.gov Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. | — | Recruiting | — | — | — |
NCT05505825CT.gov A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer | — | Completed | — | — | — |
NCT05371899CT.gov Mass Balance Study of [14C]Chiauranib | — | Completed | — | — | — |
NCT04830813CT.gov Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer | — | Completed | — | — | — |
NCT03216343CT.gov Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Chiauranib (this asset) | Akeso | P3 | B · 63 |
| Benmelstobart | Yayi He | P4 | A |
| Anti-Pd-L1 Monoclonal Antibody Shr-1316 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BBB |
| Berzosertib | National Cancer Institute (NCI) | P2 | BBB |
| Etoposide | Sichuan University | P4 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Veliparib | Central European Society for Anticancer Drug Research | P2 | BB |
| Carboplatin | University of Maryland, Baltimore | P4 | BB |
| Irinotecan | Sichuan University | P4 | BB |
+42 more in the Small Cell Lung Carcinoma cohort
Other indications for Chiauranib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Cancer | — | P3 | B · 58 |
| Triple-Negative Breast Carcinoma | — | P2 | CCC · 53 |
| Non-Hodgkin Lymphoma | — | P1/2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Chiauranib in Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/chiauranib-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →